🇺🇸 FDA
Patent

US 11026920

Use of NK-1 receptor antagonist serlopitant in pruritus

granted A61KA61K31/403A61K31/4035

Quick answer

US patent 11026920 (Use of NK-1 receptor antagonist serlopitant in pruritus) held by Vyne Therapeutics Inc. expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vyne Therapeutics Inc.
Grant date
Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/403, A61K31/4035, A61K45/06, A61K47/10